64 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
a clinical trial has commenced that a change in CRO is warranted. There can be no assurance that we will be able to negotiate and enter into appropriate … product candidates we may develop will prove safe in humans. There can be no assurance that any of the product candidates developed through our TORPEDO
8-K
EX-10.2
km1wyslgkb
30 May 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-10.1
and7puoes 5uaoe
30 May 23
Entry into a Material Definitive Agreement
7:30am